Publicaciones científicas

10 Publicaciones científicas disponibles

  • The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    28 de mayo de 2019 | Revista: Nature Communications

    Martínez-Vélez N (1,2,3), Garcia-Moure M (1,2,3), Marigil M (1,2,3), González-Huarriz M (1,2,3), Puigdelloses M (1,2,4), Gallego Pérez-Larraya J (1,2,4), Zalacaín M (1,2,3), Marrodán L (1,2,3), Varela-Guruceaga M (1,2,3), Laspidea V (1,2,3), Aristu JJ (1,5), Ramos LI (1,5), Tejada-Solís S (1,6), Díez-Valle R (1,6), Jones C (7,8), Mackay A (7,8), Martínez-Climent JA (1,9), García-Barchino MJ (1,9), Raabe E (10,11), Monje M (12), Becher OJ (13), Junier MP (14), El-Habr EA (14), Chneiweiss H (14), Aldave G (15), Jiang H (16), Fueyo J (16,17), Patiño-García A (1,2,3), Gomez-Manzano C (18), Alonso MM (19,20,21).

    (1) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (8) Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (9) Division of Hematopoietic Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, CIBERONC, Pamplona, Pamplona, Navarra, Spain.
    (10) Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (11) Division of Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (12) Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
    (13) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (14) CNRS UMR8246, Inserm U1130, Neuroscience Paris Seine - IBPS, Sorbonne Universities, Paris, France.
    (15) Division of Pediatric Neurosurgery, Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
    (16) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (17) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (18) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (19) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (20) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (21) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.


  • Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models

    29 de noviembre de 2018 | Revista: BMC Cancer

    Collantes M (1,2), Martínez-Vélez N (3), Zalacain M (3,2), Marrodán L (3,2), Ecay M (4), García-Velloso MJ (1,2), Alonso MM (3,2), Patiño-García A (3,2), Peñuelas I (5,6,7).

    (1) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Avenida Pío XII, 36 31008, Pamplona, Spain.
    (2) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (3) Departamento de Pediatría, Clínica Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (4) Small Animal Imaging Research Unit, CIMA, Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (5) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Avenida Pío XII, 36 31008, Pamplona, Spain.
    (6) Small Animal Imaging Research Unit, CIMA, Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (7) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.


  • Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis

    12 de mayo de 2016 | Revista: The Journal of Pathology

    Zandueta C (1), Ormazábal C (1), Perurena N (1), Martínez-Canarias S (1), Zalacaín M (2), San Julián M (3), Grigoriadis AE (4), Valencia K (1), Campos-Laborie FJ (5), Rivas JL (5), Vicent S (1,6), Patiño-García A (3,6), Lecanda F (1,6).

    (1) Program in Solid Tumors and Biomarkers, Division of Oncology, Center for Applied Biomedical Research (CIMA), University of Navarra, Pamplona, Spain.
    (2) Departments of Pediatrics, Orthopedics, Clínica Universidad de Navarra (CUN), School of Medicine, University of Navarra, Pamplona, Spain.
    (3) Orthopedics, Clínica Universidad de Navarra (CUN), School of Medicine, University of Navarra, Pamplona, Spain.
    (4) Department of Craniofacial Development and Stem Cell Biology, Guy's Hospital, King's College, London, UK.
    (5) Bioinformatics and Functional Genomics Research Group. Cancer Research Center (IBMCC-CIC), CSIC and University of Salamanca (CSIC/USAL), Salamanca, Spain.
    (6) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. 


  • Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival

    1 de enero de 2012 | Revista: Cancer Biomarkers

    Folio C, Zalacain M, Zandueta C, Ormazábal C, Sierrasesúmaga L, San Julián M, de las Rivas J, Toledo G, Lecanda F, Patiño-García A.
    Laboratory of Pediatrics, University Clinic of Navarra, Pamplona, Spain.

COVID-19